BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25

• Press Releases

  AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15

  September 8, 2026

   · 

  1 min read
• Press Releases

  Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease

  September 8, 2026

   · 

  5 min read
• 

  Neuroscience

  Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints

  While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in secondary and exploratory measures.

  September 8, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

  September 8, 2026

   · 

  12 min read
• Press Releases

  Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

  September 8, 2026

   · 

  6 min read
• Press Releases

  Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

  September 8, 2026

   · 

  12 min read
• Press Releases

  MediciNova to Participate in Two Investor Conferences in September 2026

  September 8, 2026

   · 

  5 min read
• Press Releases

  RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026

  September 8, 2026

   · 

  1 min read
• Press Releases

  PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure

  September 8, 2026

   · 

  4 min read
• Press Releases

  Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

  September 8, 2026

   · 

  5 min read